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Abstract
Background As of 2014, there were approximately 8300
patients with a functioning liver transplant in the UK
Transplant Registry, with 880 liver transplants performed
in 2013–2014 alone. Tacrolimus, typically used in combi-
nation with steroids and mycophenolate mofetil, currently
represents the cornerstone of post-transplant immunosup-
pression in liver transplant recipients.
Objectives The objective of the present study was to
evaluate the cost-effectiveness of prolonged-release (PR)
tacrolimus (Advagraf, Astellas Pharma Inc., Tokyo,
Japan) versus branded immediate-release (IR) tacrolimus
(Prograf, Astellas Pharma Inc., Tokyo, Japan) in liver
transplant recipients in the UK.
Methods A model was developed in Microsoft Excel to
estimate costs associated with immunosuppressive medi-
cations and retransplantation. Three-year patient and graft
survival data were taken from a recent retrospective reg-
istry analysis and dose data were taken from prescribing
information. Costs in 2014 pounds sterling were taken from
the British National Formulary and the National Health
Service National Tariff.
Results Over a 3-year time horizon, the numbers needed
to treat with PR tacrolimus relative to IR tacrolimus were
14 to avoid one graft loss and 18 to avoid one death. The
model was sensitive to dosing assumptions, with
incremental cost estimates varying between a saving of
£1642 (standard deviation £885) per patient, assuming the
same per-kilogram dosing of PR tacrolimus (Advagraf)
and IR tacrolimus (Prograf) and an increase of £1350
(£964) using RCT dose data.
Conclusion Data from a recent analysis of routine clinical
practice data in liver transplant recipients on PR tacrolimus
and IR tacrolimus showed significant differences in long-
term graft survival in favor of PR tacrolimus. Modeling
these data in the UK showed that, over a 3-year time
horizon, one graft would be saved for every 14 patients
treated with PR tacrolimus with minimal impact on costs
when compared with branded IR tacrolimus (Prograf).
Key Points
Recent data from routine clinical practice shows that
once-daily prolonged-release formulations of
tacrolimus result in improved graft survival in liver
transplant recipients relative to twice-daily
immediate-release tacrolimus.
Based on these data, a model was constructed to
estimate life expectancy, numbers needed to treat to
avoid graft failure and death, and costs associated
with immunosuppressive medications and graft
failure over 3 years after transplantation.
While model outcomes were sensitive to tacrolimus
dosing assumptions, prolonged-release tacrolimus
(Advagraf) resulted in improved patient and graft
survival and reduced costs when compared with
branded IR tacrolimus (Prograf) in the base case
analysis.
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1 Introduction
Liver transplantation is a highly effective treatment option
for patients with end-stage liver disease, and as of 2014
there were approximately 8300 patients with a functioning
liver transplant in the UK Transplant Registry, up from
7600 in 2009 [1]. One-year graft survival rates are now
over 80 % and longer-term graft and patient survival have
increased dramatically since the first liver transplants were
conducted in the 1960s [2]. While these improvements are
a result of changes to many aspects of operative and peri-
operative treatment implemented since the early trans-
plants, improvements in post-transplant immunosuppres-
sion are generally considered to be the most important
innovation. Indeed, previous studies have divided large
liver transplant populations into separate ‘‘eras’’ based on
the availability of new immunosuppressive regimens and
induction therapies at the time of transplant [3]. Jain et al.
[3] selected the introduction of ciclosporin, muromonab-
CD3 (OKT3), and tacrolimus as the cut-off points for three
eras, corresponding to the periods spanning 1981–85,
1986–90, and 1991–98 [3]. Their study of 4000 liver
transplant recipients showed that survival in the tacrolimus
era was significantly improved relative to the previous eras,
reporting 10-year survival of 60 % compared with 52 %
and 53 % for the OKT3 and ciclosporin eras, respectively
[3].
The tacrolimus registration trials for liver transplant,
published in 1994, showed a significant reduction in the
incidence of acute rejection relative to ciclosporin,
although no significant differences in mortality or graft loss
compared to ciclosporin were observed over 12 months [4,
5]. Specifically, the registration trials compared ciclosporin
with twice-daily, immediate-release (IR) tacrolimus (Pro-
graf, Astellas Pharma Inc., Tokyo, Japan) that is now a
cornerstone of immunosuppressive therapy in liver trans-
plant recipients [6]. Since the publication of the registration
trials, tacrolimus has been reformulated into a once-daily,
prolonged-release (PR) formulation (Advagraf, Astellas
Pharma Inc., Tokyo, Japan), which received European
Medicines Agency (EMA) marketing authorization in 2007
[7]. In the European public assessment report accompa-
nying the marketing authorization, regarding Advagraf the
EMA noted that ‘‘it is expected that it may help to improve
compliance with dosing’’ and that the modified-release
profile ‘‘would be expected to improve the variability in the
exposure to tacrolimus’’ [8]. Several studies in liver
transplant recipients have since confirmed that intra-patient
variability is indeed reduced with PR tacrolimus relative to
IR tacrolimus, and that the majority of patients prefer once-
daily dosing over twice-daily dosing and are more adherent
to the once-daily regimen [9–14]. One randomized
controlled trial (RCT) of PR versus IR tacrolimus has been
conducted to date, in which PR tacrolimus showed non-
inferiority relative to IR tacrolimus in terms of the primary
endpoint of biopsy-confirmed rejection at 24 weeks [15].
While the open-label 12-month extension of the RCT also
showed non-inferiority in secondary endpoints of graft and
patient survival, recent retrospective analyses of 3-year
follow-up data from the European Liver Transplant Reg-
istry (ELTR) have been published demonstrating signifi-
cant improvements in graft survival and numerical but not
statistically significant improvements in patient survival
with PR tacrolimus relative to IR tacrolimus [16]. Given
these emerging data, the increasing size of the patient
population with a functioning liver graft, and the con-
comitant increase in healthcare expenditure in these
patients, the aim of the present analysis was to use data
from the ELTR analysis to project treatment costs, patient
and graft life expectancy, and numbers needed to treat to




A model was constructed in Microsoft Excel (Microsoft
Corporation, Redmond, WA USA) to project cost and
effectiveness outcomes in de novo adult liver transplant
recipients using PR tacrolimus (Advagraf) or branded IR
tacrolimus (Prograf) as the primary immunosuppressive
regimen in the UK setting. Patient and graft survival rates
were based on a retrospective analysis of data from the
ELTR [16]. The ELTR includes data on liver transplant
recipients from 145 European transplant centers, 21 of
which prescribed both PR and IR tacrolimus and were
included in the analysis. In brief, Adam et al. [16] con-
ducted a retrospective database analysis of primary liver
transplant patients C18 years old who underwent their first
liver transplant between January 2008 and December 2012
and received PR tacrolimus or IR tacrolimus, with or
without concomitant immunosuppressive agents, within the
first month after transplantation. Two analyses of the data
were conducted. The first analysis was of a modified intent-
to-treat (mITT) population that excluded all patients with
less than 1 month of post-transplant follow-up (to avoid the
confounding factors of post-operative complications). The
second analysis looked at the same endpoints in a
propensity-score matched (PSM) population, in which PR
and IR tacrolimus patients were paired in a 1:2 ratio based
on a propensity score. The propensity score was based on
recipient age, recipient human immunodeficiency virus,
hepatitis C and hepatocellular carcinoma status, United
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Network for Organ Sharing (UNOS) status, creatinine
levels, donor age, date of transplantation, total ischemia
time, and administration of other immunosuppressive
medications early post-transplant [ciclosporin, mycophe-
nolate mofetil (MMF), corticosteroids, daclizumab, and
basiliximab].
The Kaplan–Meier analyses of patient and graft survival
in the mITT cohort were used to calculate rates of graft loss
and mortality in the base case analysis. Retransplantation
rates were derived based on the assumption that retrans-
plantation accounts for the entire difference between patient
and graft survival. Since the ELTR analysis did not report
tacrolimus dosing, data from the respective summaries of
product characteristics (SPC) were used to establish the
initial doses of IR and PR tacrolimus in the base case, both
of which were taken to be the mid-point of the SPC-rec-
ommended starting dose range of 0.10–0.20 mg/kg/day.
The initial dose was assumed to be maintained for 1 year
after which the dose in both treatment arms was switched to
match the end-of-study (EOS) IR tacrolimus dose (0.58 mg/
kg/day) from the Trunecˇka et al. RCT [15]. Mean patient
bodyweight was taken to be 77.2 kg based on the weighted
average from Trunecˇka et al. [15].
The model was designed to evaluate the number needed
to treat (NNT) to avoid one graft loss or one death with PR
tacrolimus relative to IR tacrolimus, the life expectancy
with PR relative to IR tacrolimus, and the number of graft
years saved with PR relative to IR tacrolimus in addition to
the costs associated with retransplantation and primary
immunosuppressive therapy with each formulation.
2.2 Unit Costs
For the base case analysis, the per-milligram cost of PR
tacrolimus (Advagraf) and branded IR tacrolimus (Pro-
graf) were taken from the September 2014 British
National Formulary (BNF; Table 1) [17]. The BNF was
also used as the source of an alternative per-milligram cost
of generic IR tacrolimus (Adoport, Sandoz International
GmbH, Holzkirchen, Germany) in one-way sensitivity
analysis. The mean cost of liver retransplantation was
assumed to be 1.84 times more costly than a first transplant
based on the overall retransplant cost ratio reported by
Azoulay et al. in a single-center study of 1038 first liver
transplants and 139 retransplants [18].
2.3 Perspective, Time Horizon, and Discounting
The base case analysis was performed over a 3-year time
horizon to avoid extrapolation of the underlying graft and
patient survival data from the ELTR. The model reported
all outcomes annually and applied half-cycle correction to
eliminate any systematic over- or underestimation of costs
and effects. Cost and effectiveness outcomes were mea-
sured from the perspective of the UK healthcare payer, and
future costs and effects were discounted at 3.5 % per
annum in the base case. Sensitivity analyses were per-
formed with a 1.5 % annual discount rate for both costs and
effects in line with guidance from the National Institute for
Health and Care Excellence [19]. All costs were reported in
2014 pounds sterling (£).
2.4 Threshold, Probabilistic, and One-Way
Sensitivity Analyses
All analyses were run as probabilistic sensitivity analyses,
in which uncertainty around patient body weight, the cost
of liver retransplantation, and the Kaplan–Meier projec-
tions of mortality and graft loss were captured. Standard
errors around the Kaplan–Meier curves were estimated
based on binomial proportion 95 % confidence intervals
around the percentage of patients and grafts surviving at
each time point (Eq. 1), ensuring that both were mono-
tonically decreasing functions and that patient survival
always equaled or exceeded graft survival.
Equation 1: Assumed standard error around Kaplan–






pð1  pÞ ð1Þ
Patient body weight was sampled using the weighted
standard deviation (SD) body weight from the Trunecˇka
et al. [15] RCT and a confidence interval around the ratio
of retransplantation costs to first transplant costs was
Table 1 Unit costs in cost-effectiveness analyses of prolonged-release (PR) tacrolimus versus branded and generic immediate-release (IR)
tacrolimus as the primary immunosuppressive agents in renal transplant recipients
Cost item Cost References
PR tacrolimus (Advagraf) 1.43 (£ per mg) British National Formulary 68 [17]
IR tacrolimus (Prograf) 1.61 (£ per mg) British National Formulary 68 [17]
IR tacrolimus (Adoport), one-way sensitivity analysis only 1.11 (£ per mg) British National Formulary 68 [17]
Liver retransplantation 35,164.23 (£) NHS Tariff Information
£ 2014 pounds sterling, IR immediate-release, NHS, National Health Service, PR prolonged-release
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approximated using Fieller’s theorem from standard
deviations reported in the Azoulay et al. study [20].
The sensitivity of the model to changes in individual
input parameters was explored in a series of one-way
sensitivity analyses. Specifically, sensitivity analyses were
conducted around the base case analysis in which the
ELTR PSM population data were used in place of the
mITT population. The sensitivity to dosing assumptions
was investigated by using dosing data directly from the
Trunecˇka et al. [15] study for the first year of simulation,
followed by holding the dose steady at the final dose as
reported by Trunecˇka et al. at day 365. A further dosing
sensitivity analysis was conducted in which a rational
model (i.e., a ratio of a first- and second-order polynomials)
was fitted to the Trunecˇka dose curves for each arm of the
simulation. The correlation coefficients (R2) of the rational
model to the extracted data sets were 0.985 and 0.982 for
PR tacrolimus and IR tacrolimus, respectively, and the
models were used to extrapolate out to the full 3-year time
horizon. Finally, four cost-centric sensitivity analyses were
conducted; one in which the per-milligram cost of IR
tacrolimus was set to the same as that for PR tacrolimus, a
second in which the per-milligram cost of generic IR
tacrolimus (Adoport) was used in place of the branded IR
tacrolimus (Prograf) cost, and two analyses of retrans-
plantation costs; one in which the cost of retransplantation
was set to the same cost as a first transplant and a second in
which the cost of retransplantation was abolished.
In line with guidance from the International Society for
Pharmacoeonomics and Outcomes Research, a determin-
istic threshold analysis was conducted to establish the PR
tacrolimus (Advagraf) drug cost at which overall costs
would be equivalent in the two treatment arms [21]. The
threshold analysis was conducted using both the base case
cost of branded IR tacrolimus (Prograf) and the cost of
generic IR tacrolimus (Adoport).
3 Results
In the probabilistic base case analysis, graft and patient
survival estimates matched those from the ELTR mITT
analysis (Fig. 1). The mean NNT to avoid one graft loss
with PR tacrolimus relative to IR tacrolimus over 3 years
was 14 patients, while the corresponding NNT to avoid one
death was 18. Mean (SD) patient life expectancy over the
3-year time horizon was 31.52 (0.22) months in the PR
tacrolimus arm versus 30.62 (0.09) months with IR tacro-
limus, representing an increase of 0.89 (0.23) months,
while graft survival was 1.07 (0.21) months higher with PR
tacrolimus at 31.2 (0.19) months versus 30.2 (0.09) months
with IR tacrolimus (Table 2).
These increases in effectiveness were accompanied by
mean (SD) per-patient cost savings with PR tacrolimus
(Advagraf) of £1642 (885) over 3 years, with PR tacro-
limus (Advagraf) thereby exhibiting dominance over the
branded IR formulation (Prograf). PR tacrolimus (Adva-
graf) was less costly and more effective than branded IR
tacrolimus (Prograf) in 9559 (95.6 %) of 10,000 iterations
(Fig. 2). PR tacrolimus (Advagraf) was more costly and
more effective than branded IR tacrolimus (Prograf) in
439 analyses, in which the mean incremental cost-effec-
tiveness ratio (ICER) was £4282 per life year gained. Two
analyses (0.02 % of model iterations) showed reduced
effectiveness and reduced costs with PR tacrolimus (Ad-
vagraf) relative to branded IR tacrolimus (Prograf).
Fig. 1 Patient and graft survival over time based on the propensity-score matched and modified intent-to-treat analyses of the European Liver
Transplant Registry data. IR immediate-release, mITT modified intent-to-treat, PSM propensity-score matched, PR prolonged-release
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Findings of one-way sensitivity analyses are presented
in Table 3. The largest effect on the incremental cost
outcomes was observed when the dose data for each arm
was based on the dose curves reported in the Trunecˇka
et al. [15] RCT, in which PR tacrolimus (Advagraf) was
associated with an increase in costs of £1350 per patient
over 3 years relative to branded IR tacrolimus (Prograf),
resulting in an ICER of £18,255 per life year gained.
Switching the per-milligram IR tacrolimus cost to that of
generic tacrolimus (Adoport) resulted in incremental
costs of £1556, yielding an ICER of £21,078 per life year
gained for PR tacrolimus (Advagraf) relative to generic
IR tacrolimus (Adoport). Using the PSM outcomes data
from the ELTR had a large effect on both incremental costs
and effects; incremental life expectancy increased to 2.00
months, while cost savings decreased to £763 as a result of
the increased patient and graft survival with PR tacrolimus
(Advagraf). The rational model fit and extrapolation from
the Trunecˇka dosing curves also had a relatively large
effect on cost, reducing modelled cost savings with PR
tacrolimus (Advagraf) to £1237 per patient over 3 years.
Deterministic threshold analysis showed that the PR
tacrolimus (Advagraf) breakeven price (the price at which
the cost in both model arms is equivalent) would be £1.77
per milligram when branded IR tacrolimus (Prograf) was
used for the analysis, £0.34 per milligram higher than the
current per-milligram cost of PR tacrolimus (Advagraf) in
the BNF. Threshold analysis using the cost of generic IR
tacrolimus (AdoportR)) resulted in a breakeven price of
£1.28 per milligram, £0.15 per milligram lower than the
per-milligram cost of PR tacrolimus (Advagraf) in the
BNF. The additional £0.15 per milligram for Advagraf
yielded 0.89 additional months of life over the model time
horizon (resulting in the ICER of £21,078 per life year
gained as reported in one-way sensitivity analysis,
Table 3).
Table 2 Top-line probabilistic results from a 3-year analysis of the cost-effectiveness of prolonged-release (PR) versus immediate-release (IR)
tacrolimus in liver transplant recipients in the UK
IR tacrolimus (Prograf) PR tacrolimus (Advagraf) Difference
Cost of immunosuppression, £ 10,405 (2203) 9469 (2006) -937 (208)
Cost of retransplantation, £ 1654 (443) 949 (689) -705 (820)
Total cost, £ 12,062 (2245) 10,420 (2130) -1642 (885)
Life expectancy, months 30.62 (0.09) 31.52 (0.22) ?0.89 (0.23)
Graft life expectancy, months 30.16 (0.09) 31.23 (0.19) ?1.07 (0.21)
Annualized probability of graft loss 0.064 0.039 -0.025
NNT to avoid graft loss with PR vs. IR tacrolimus 14
Annualized probability of death 0.058 0.039 -0.019
NNT to avoid death with PR vs. IR tacrolimus 18
Values are presented as mean (standard deviation)
£ 2014 pounds sterling, IR immediate-release, NNT number needed to treat, PR prolonged-release
Fig. 2 Cost-effectiveness
scatterplot showing incremental
per-patient costs and life
expectancy from 10,000 model
iterations over a 3-year time
horizon. IR immediate-release,
PR prolonged-release
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4 Discussion
The present study showed that, based on a recent retro-
spective analysis of data from 4367 patients in the ELTR,
PR tacrolimus would be expected to be associated with
gains in life expectancy and graft survival relative to IR
tacrolimus, while reducing costs borne by the healthcare
payer (in comparison to branded IR tacrolimus (Prograf).
As with any modeling analysis, the present study has a
number of limitations that should be acknowledged. The
largest limitation of the analysis was the use of heteroge-
neous data sources to model the clinical outcomes and
dosing of the PR and IR tacrolimus regimens. Dose data
were not recorded in the ELTR and as such did not form part
of the retrospective analysis by Adam et al. [16] that
underpinned the clinical aspects of the model. The most
important consequence of this data heterogeneity was that
clinical effectiveness outcomes were derived from a dif-
ferent dataset from the estimates of pharmacy dosing and
hence also pharmacy costs. To establish the effect of dosing
assumptions on model outcomes, an extensive series of
sensitivity analyses were conducted around the base case
analysis, including switching the model to use dosing data
from the Trunecˇka et al. [15] study and either holding the
projected dose flat at the EOS dose or projecting the dose
out using a rational model fit to the Trunecˇka dose data.
The base case analysis used the BNF unit costs for PR
tacrolimus (Advagraf) and IR tacrolimus (Prograf) to
reflect the tacrolimus formulations used in the ELTR study
on which the clinical outcomes were based. Other generic
formulations of IR tacrolimus are listed in the BNF,
including Adoport, which is currently the cheapest twice-
daily formulation at £1.11 per milligram. Sensitivity
analysis using the Adoport price showed that using PR
tacrolimus (Advagraf) in place of Adoport would result
in an ICER of £21,078 per life year gained based on an
increase in life expectancy of 0.89 months, while threshold
analysis showed the PR tacrolimus (Advagraf) breakeven
price to be £0.15 per milligram (10.5 %) lower than the
current PR tacrolimus (Advagraf) list price. Taken toge-
ther, the analyses show that the additional £0.15 per mil-
ligram spend on PR tacrolimus (Advagraf) resulted in an
average of 0.89 additional months of life per patient over a
3-year time horizon.
Certain limitations should also be noted pertaining to the
inclusion of retransplantation costs. The retransplantation
Table 3 Summary of one-way sensitivity analyses around the base case analysis












Base case 30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 12,062 (2245) 10,420 (2130) -1642 (885) PR dominant
1.5 % discount rate 31.48 (0.09) 32.41 (0.22) ?0.93 (0.24) 12,502 (2290) 10,788 (2170) -1714 (895) PR dominant
Trunecˇka IR dosing in both
arms, held at EOS dose
[15]
30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 10,102 (1824) 8641 (1760) -1461 (866) PR dominant
Trunecˇka IR and PR dosing,
held at EOS dose [15]
30.62 (0.09) 31.51 (0.22) ?0.89 (0.23) 10,098 (1837) 11,449 (2340) ?1350 (964) 18,255
Rational model fit to
Trunecˇka IR and PR dose
curves [15]
30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 7445 (1298) 6208 (1301) -1237 (849) PR dominant
ELTR PSM data used in
place of mITT[15]
30.05 (0.21) 32.06 (0.21) ?2.00 (0.30) 11,557 (2346) 10,794 (2221) -763(1220) PR dominant
IR cost equivalence with PR
tacrolimus
30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 10,973 (2114) 10,420 (2130) -553 (855) PR dominant
IR cost equivalence with
generic IR tacrolimus
(Adoport)
30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 8862 (1578) 10,420 (2130) ?1556 (981) 21,078
Cost of retransplant same as
first transplant
30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 11,341 (2189) 10,005 (2025) -1336 (513) PR dominant
Cost of retransplant
abolished
30.62 (0.09) 31.52 (0.22) ?0.89 (0.23) 10,476 (2186) 9533 (1989) -943 (207) PR dominant
Values are presented as mean (standard deviation)
£ 2014 pounds sterling, ELTR European Liver Transplant Registry, EOS end of study, IR immediate-release, mITT modified intent-to-treat, PR
prolonged-release, PSM propensity-score matched
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cost estimate was based on the NHS tariff for an adult
hepatobiliary transplant multiplied by a cost ratio (of sec-
ond versus first liver transplant) derived from a single-
center analysis [18]. While the size of the population
analyzed was large enough (N = 1177) to capture a wide
range of surgical complications and indications for trans-
plant and retransplant, center-specific practices and proto-
cols may have affected the cost estimates presented and the
final cost estimate may not be applicable to other centers.
Retransplantation was captured in the model as the dif-
ference between patient survival and graft survival. Given
that retransplantation is the only treatment option for liver
graft failure, this assumption is clinically realistic but,
while the inclusion of retransplantation is also economi-
cally important given the high cost associated with the
procedure, its role as a driver of incremental costs is
challenging. Notably, local organ availability and center-
specific ethical considerations such as outcomes-based
versus urgency-based approaches to retransplant prioriti-
zation make the incidence of retransplantation less of a
clinical consideration and more of a logistical and ethical
issue [22]. To establish the extent to which retransplanta-
tion was driving cost outcomes, sensitivity analyses were
conducted in which the cost of retransplantation was firstly
set to the same cost as a first liver transplant and, in a
separate analysis, abolished completely. Both analyses
yielded cost savings with PR tacrolimus (Advagraf), but
the magnitude of the savings was reduced relative to the
base case analysis.
As the main source of clinical data in the present anal-
ysis, the ELTR study design and its limitations should also
be considered when interpreting the findings of the present
analysis. An editorial that accompanied the original
manuscript noted that the ELTR data is subject to reporting
bias (in that it is collected on a voluntary basis) and that
characteristics of the patients on IR and PR tacrolimus
differed in terms of their age, concomitant mediation use,
serum creatinine levels, hepatitis delta or hepatocellular
carcinoma (HCC) as the primary indication, and donor age
[23]. The PSM analysis attempted to address these known
differences, but extraneous factors such as socioeconomic
differences may have persisted and, as noted in the edito-
rial, 49 % of patients on PR tacrolimus remained unmat-
ched in the PSM analysis. The lack of randomization may
have also resulted in bias arising from assignment of sicker
patients to receive the longer established IR tacrolimus
regimen and the effect of the choice of included ELTR
centers should not be ignored. The authors of the ELTR
data analysis noted that the 21 centers using PR tacrolimus
and IR tacrolimus were selected ‘‘to prevent center bias,’’
[16] but it is conceivable that outcomes with IR tacrolimus
in the 21 included centers may differ from those in the
remaining 124 centers participating in the ELTR using IR
tacrolimus exclusively.
While such criticisms of observational data are entirely
valid, these issues are not unique to data from routine
clinical practice, with small-scale RCTs suffering from
many of the same methodological issues. In the present
analysis, the mITT data were used in the base case and a
sensitivity analysis was conducted with the PSM data to
explore the extent to which the mortality and graft loss
outcomes affected the analysis. PR tacrolimus (Advagraf)
remained cost saving in the PSM analysis, but the life
expectancy benefit increased to 2.00 months over the
3-year time horizon, extending the dominance of PR
tacrolimus (Advagraf) over branded IR tacrolimus
(Prograf).
Certain drivers of costs were intentionally omitted from
the present analysis, including surgical complications, new
onset diabetes after transplantation, cytomegalovirus
infection, and the myriad costs associated with various
recurrent indications for liver transplant such as HCC and
HCV. While these sequelae and complications contribute
to the absolute cost of treating liver transplant recipients,
differences in the incidence would not be anticipated to
drive incremental cost or effectiveness outcomes between
two tacrolimus formulations. Cost estimates in the present
analysis should not therefore be considered instructive for
the purposes of budget impact analysis. Based on the
emerging data from the ELTR in concert with the previ-
ously established non-inferiority in terms of biopsy-con-
firmed acute rejection, we consider the model to be
comprehensive in terms of its ability to capture drivers of
incremental costs and effects between the two tacrolimus
formulations.
5 Conclusion
Based on the present analysis, PR tacrolimus would be
expected to prevent one graft loss for every 14 patients
and one death for every 18 patients initiated on PR
tacrolimus rather than IR tacrolimus. Furthermore, PR
tacrolimus (Advagraf) would be likely to reduce costs
associated with immunosuppressive treatment and
retransplantation by up to £ 1642 (885) per patient over 3
years versus branded IR tacrolimus (Prograf). These
findings, combined with the well established patient
preference for once-daily over twice-daily dosing [10,
13], and the recent publication of clinical data showing a
graft survival benefit with once-daily tacrolimus [16],
provide a strong case for the preferential use of PR
tacrolimus over IR tacrolimus in adult liver transplant
recipients in the UK setting.
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